Reporting from the ESMO Congress 2021, Robin Cornelissen discusses novel precision medicine strategies for patients with NSCLC. He explains the response results from the ZENITH20-4 cohort in first-line treatment with poziotinib for HER2 exon 20 mutated NSCLC and reviews promising results from the Atalante-1 phase III study, testing a vaccine strategy in patients with HLA-A2+ NSCLC after immunotherapy failure. Finally, he explains the outcomes from datopotamab deruxtecan in mNSCLC with actionable genomic alterations by detailing the encouraging results from the TROPION-PanTumor01 study.
Abstracts:
LBA46 - Efficacy and Safety of Poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational Phase 2 study (ZENITH20-4) - Dr Robin Cornelissen, NL
LBA47 - Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Final results of Phase 3 Atalante-1 randomised trial - Prof Benjamin Besse, FR
LBA49 - Outcomes in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan (Dato-DXd) in solid tumors - Dr Edward Garon, US
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.
Produced by the European Society for Medical Oncology
[ Ссылка ]
